Ubiquinone 9
Spécifications
303-97-9Numéro CAS
2,3-dimethoxy-5-methyl-6-[(2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl]cyclohexa-2,5-diene-1,4-dioneNom IUPAC
C54H82O4Formule chimique
795.2 g/molMasse molaire
Coenzyme Q9; 303-97-9; Ubiquinone 9; Ubiquinone-9; Ubiquinone 45; CoQ9; Ubiquinone-45; MGW7TYF2DQ; DTXSID601317880; 2,3-Dimethoxy-5-methyl-6-((2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaen-1-yl)cyclohexa-2,5-diene-1,4-dione; NSC-226993; 2,3-dimethoxy-5-methyl-6-[(2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl]cyclohexa-2,5-diene-1,4-dione; CHEBI:18160; 2,3-dimethoxy-5-methyl-6-[(2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaen-1-yl]cyclohexa-2,5-diene-1,4-dione; 2,5-cyclohexadiene-1,4-dione, 2,3-dimethoxy-5-methyl-6-((2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaen-1-yl)-; ubiquinone Q-9; 2,3-dimethoxy-5-methyl-6-((2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl)cyclohexa-2,5-diene-1,4-dione; RefChem:127404; DTXCID60909085; Ubiquinone Q9; Coenzyme Q(sub 9); Ubiquinone Q(sub 9); CoQ(sub 9); COENZYMEQ9; MFCD00056635; Coenzyme Q(9); C54H82O4; UNII-MGW7TYF2DQ; NSC 226993; BRN 1900081; Ubiquinone Q9;CoQ9;Ubiquinone 9; Ubiquinone9; coenzyme-Q9; ubiquinone(9); UUGXJSBPSRROMU-WJNLUYJISA-N; Coenzyme Q9?; Coenzyme Q9 (Standard); Ubidecarenone impurity D CRS; UBIQUINONE Q9 (STN); 4-08-00-03313 (Beilstein Handbook Reference); orb1220971; orb1301680; CHEMBL2252965; SCHEMBL27472926; Butyryl-CoA lithium salt hydrate; EX-A14857; LMPR02010004; MSK158298; NSC226993; AKOS027307694; Coenzyme Q9, >=96.0% (HPLC); CS-6359; EBC-106040; FC20538; HY-101415R; Ubidecarenone Impurity 1(Coenzyme Q9); 2,5-Cyclohexadiene-1,4-dione, 2,3-dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaenyl)-, (all-E)-; AS-77794; p-Benzoquinone, 2,3-dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaenyl)-; p-Benzoquinone, 2,3-dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaenyl)- (VAN); SY074807; HY-101415; T5573; UBIDECARENONE IMPURITY D [EP IMPURITY]; C01967; F787628; 2-methyl-3-nonaprenyl-5,6-dimethoxy-1,4-benzoquinone; Q27102857; Ubidecarenone impurity D, European Pharmacopoeia (EP) Reference Standard; (all-E)-2,3-Dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaenyl)-2,5-cyclohexad iene-1,4-dione; (all-E)-2,3-dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaenyl)-2,5-cyclohexadiene-1,4-dione; 2,3-dimethoxy-5-methyl-6-[(2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaen-1-yl]-1,4-benzoquinone; 2,3-dimethoxy-5-methyl-6-[(2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl]-1,4-benzoquinone; 2,4-dione, 2,3-dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaenyl)-, (all-E)-; p-Benzoquinone,3-dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaenyl)-Synonymes
